News
Important Only
Prada's CEO say group looks at M&A opportunities when they come around
MILAN, March 4 (Reuters) - Italian luxury group Prada 1913.F looks at M&A opportunities when they arise, Chief Executive Andrea Guerra told analysts in a conference call on Tuesday."On one side we are focused on our brands, on the other side ... when things come around you'll look at the...Reuters
Tue, Mar 4
Xeris Biopharma Holdings Inc expected to post a loss of 6 cents a share - Earnings Preview
Xeris Biopharma Holdings Inc XERS.OQ XERS.O is expected to show a rise in quarterly revenue when it reports results on March 6 for the period ending December 31 2024The Chicago Illinois-based company is expected to report a 30.9% increase in revenue to $58.104 million from $44.39 million a year ag...Reuters
Tue, Mar 4
Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne
March 4 (Reuters) - Dermata Therapeutics Inc DRMA.O:DERMATA ANNOUNCES THAT LAST PATIENT COMPLETES LAST VISIT IN PIVOTAL XYNGARI™ PHASE 3 STAR-1 CLINICAL TRIAL FOR ACNEDERMATA THERAPEUTICS INC - TOPLINE DATA EXPECTED BY END OF MARCH 2025Reuters
Tue, Mar 4
ProFrac Holding Corp expected to post a loss of 28 cents a share - Earnings Preview
ProFrac Holding Corp ACDC.OQ ACDC.O is expected to show a fall in quarterly revenue when it reports results on March 6 for the period ending December 31 2024The Willow Park Texas-based company is expected to report a 2.0% decrease in revenue to $479.263 million from $489.1 million a year ago, acco...Reuters
Tue, Mar 4
Mira Pharmaceuticals Announces Approval And Initiation Of Phase 1 Clinical Trial For Ketamir-2 In Neuropathic Pain
March 4 (Reuters) - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS ANNOUNCES APPROVAL AND INITIATION OF PHASE 1 CLINICAL TRIAL FOR KETAMIR-2 IN NEUROPATHIC PAINSource text: [ID:n0001493152-25-008977]Reuters
Tue, Mar 4
Alzamend Neuro Announces Initiation Date Of Phase II Clinical Trial Of AL001 For Treatment Of Bipolar Disorder To Take Place At Massachusetts General Hospital
March 4 (Reuters) - Alzamend Neuro Inc ALZN.O:ALZAMEND NEURO ANNOUNCES INITIATION DATE OF PHASE II CLINICAL TRIAL OF AL001 FOR TREATMENT OF BIPOLAR DISORDER TO TAKE PLACE AT MASSACHUSETTS GENERAL HOSPITALReuters
Tue, Mar 4
